Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of BI 54903 versus fluticasone propionate and placebo in uncontrolled asthma
2010-023168-41Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciclesonide in asthma (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mean change from randomization baseline to end of 8-week treatment in trough FEV1. Started Jul 2011; status: completed.
02
Drugs
ciclesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2010-023168-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023168-41.